Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

PHASE3CompletedINTERVENTIONAL

Enrollment

187

Participants

Timeline

Start Date

April 21, 2009

Primary Completion Date

August 20, 2018

Study Completion Date

August 20, 2018

Conditions

LeukemiaAMLMDS

Interventions

DRUG

Azacitidine

32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston